{
    "2019-02-18": [
        [
            {
                "time": "",
                "original_text": "健帆生物：主营业务产品加速增长 买入评级",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "主营业务",
                        "加速增长",
                        "买入评级"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "健帆生物：董事集体减持 靓丽业绩能否支撑高估值？ 减持股份",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "董事",
                        "集体减持",
                        "靓丽业绩",
                        "高估值"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}